Patent · US Active

Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof

US10696688B2 · kind B2 · utility

0Cited by

2References

9Claims

0Family size

Assignee

COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH · IN

Inventors

Sandip Bibishan Bharate · Ranbir Singh Pura, IN
Shashi Bhushan · Jammu, IN
Shabber Mohammed · Atlanta, US
Santosh K. Guru · Jammu, IN
Sonali Sandip Bharate · Jammu, IN
Vikas Kumar · Jammu, IN
Girish Badrinath Mahajan · Jammu, IN
Mubashir Javed Mintoo · Jammu, IN
Dilip Manikrao Mondhe · Jammu, IN
Ram Vishwakarma · Jammu, IN

Key dates

Filing date	Nov 21, 2016
Grant date	Jun 30, 2020
Priority date	—
Expiry date	Apr 6, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D493/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention relates to fused pyrimidines of formulae I and II wherein, R1, R2 are as herein described. The present invention particularly relates to isoform selective PI3Kα inhibition and their medicinal use as anticancer agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.